External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience CTAD 2021
Roche and Genentech at

CTAD 2021

November 09 - November 12
Boston, USA / Virtual (Hybrid)
ctad-alzheimer.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Highlights
Coming soon
10:50 AM
Duration 15mins Grand Ballroom A
Phase II trial of semorinemab in mild-to-moderate Alzheimer's disease (Lauriet): Topline results
Monteiro C, Toth B, Wildsmith K, Sanabria Bohorquez S, Brunstein F, Madsen A, Dolton M, Ramakrishnan V, Abramzon D, Teng E
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:00 AM
Duration 15mins Virtual
Baseline characteristics of the GRADUATE studies: Phase III randomized, placebo-controlled studies investigating subcutaneous gantenerumab in participants with early Alzheimer’s disease
Lane C, Bullain S, Thanasopoulou A, Delmar P, Boada M, Grimmer T, Kerwin D, Fontoura P, Baudler M, Kerchner GA, Doody RS
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 15mins Virtual
Brainshuttle AD: A Phase Ib/IIa Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6102 in Participants with Prodromal or Mild-to-moderate Alzheimer’s Disease
Kulic L, Vogt A, Alcaraz F, Barrington P, Marchesi M, Klein G, Croney R, Agnew D, Abrantes JA, Jordan P, Svoboda H
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 15mins Virtual
PK/PD modeling framework to inform the clinical development of RG6102, an amyloid-targeting investigational drug with enhanced brain penetration properties
Abrantes JA, Grimm HP, Hofmann C, Buatois S, Jolivet S, Frey N, Silber Baumann H, Svoboda H, Kulic L
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:40 PM
Duration 15mins Grand Ballroom A
Comparison of the FCSRT and RBANS in screening for early ad clinical trials: Enrichment for disease progression
Teng E, Manser P, Hu N, Shah M, Pickthorn K, Blendstrup M, Faccin G, Ostrowitzki S, Sink KM
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:25 AM
Duration 15mins Grand Ballroom A
Quantification of cognitive impairments in preclinical and early Alzheimer’s disease: A proof of concept study to investigate the feasibility, adherence and preliminary clinical validity of remote smartphone-based self-assessments of cognition, function and behavior
Perumal TP, Wolfer A, Lipsmeier F, Lindemann M, Orfaniotou F, Rey-Riek S, Kurniawan IT, Watson D, Boada M, Taylor KI
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

Sign up or login to unlock the full suite of MEDICALLY features
CTAD 2021 In-Depth Report
Springer Healthcare
Open asset

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.